Yake Pharmaceutical

Yake Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for hematological malignancies and solid tumors. The company has established a robust pipeline targeting a wide range of antigens, including CD19, CD22, and BCMA, with several programs in Phase 1 and Phase 2 clinical trials. Yake Biotech focuses on addressing unmet medical needs in refractory and relapsed cancers through its proprietary cell therapy platforms. Their research extends to multi-target CAR-T cells and universal CAR-T technologies to improve efficacy and accessibility. The company operates integrated research, development, and manufacturing facilities to support its clinical programs.